Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
Status:
Withdrawn
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study of the safety and efficacy of Intravenous (IV) Ribavirin in treating
patients presenting with a probable or suspected case of viral hemorrhagic fever (either
Crimean Congo or Lassa Fever) at a military medical treatment hospital. All patients will be
treated with a 10 day course of IV Ribavirin if they meet all the inclusion and none of the
exclusion criteria.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.